Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

The site on the HIV-1 gp120 glycoprotein that binds the CD4 receptor is recognized by broadly reactive antibodies, several of which neutralize over 90% of HIV-1 strains. To understand how antibodies achieve such neutralization, we isolated CD4-binding-site (CD4bs) antibodies and analyzed 16 co-crystal structures -8 determined here- of CD4bs antibodies from 14 donors. The 16 antibodies segregated by recognition mode and developmental ontogeny into two types: CDR H3-dominated and VH-gene-restricted. Both could achieve greater than 80% neutralization breadth, and both could develop in the same donor. Although paratope chemistries differed, all 16 gp120-CD4bs antibody complexes showed geometric similarity, with antibody-neutralization breadth correlating with antibody-angle of approach relative to the most effective antibody of each type. The repertoire for effective recognition of the CD4 supersite thus comprises antibodies with distinct paratopes arrayed about two optimal geometric orientations, one achieved by CDR H3 ontogenies and the other achieved by VH-gene-restricted ontogenies.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of V3 and V3 genes.

Lin T, Lee C, Fernandez-Quintero M, Ferguson J, Han J, Zhu X Nat Commun. 2025; 16(1):1268.

PMID: 39894881 PMC: 11788443. DOI: 10.1038/s41467-025-56496-4.

Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity.

Foulkes C, Friedrich N, Ivan B, Stiegeler E, Magnus C, Schmidt D PLoS Pathog. 2025; 21(1):e1012825.

PMID: 39836706 PMC: 11774494. DOI: 10.1371/journal.ppat.1012825.

Current methods for detecting and assessing HIV-1 antibody resistance.

Odidika S, Pirkl M, Lengauer T, Schommers P Front Immunol. 2025; 15():1443377.

PMID: 39835119 PMC: 11743526. DOI: 10.3389/fimmu.2024.1443377.

Novel polymorphic and copy number diversity in the antibody IGH locus of South African individuals.

Marsden A, Corcoran M, Karlsson Hedestam G, Garrett N, Abdool Karim S, Moore P Immunogenetics. 2024; 77(1):6.

PMID: 39627383 PMC: 11615098. DOI: 10.1007/s00251-024-01363-7.

References

Diskin R, Scheid J, Marcovecchio P, West Jr A, Klein F, Gao H . Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011; 334(6060):1289-93. PMC: 3232316. DOI: 10.1126/science.1213782. View

Klein F, Diskin R, Scheid J, Gaebler C, Mouquet H, Georgiev I . Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013; 153(1):126-38. PMC: 3792590. DOI: 10.1016/j.cell.2013.03.018. View

Chen L, Kwon Y, Zhou T, Wu X, ODell S, Cavacini L . Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009; 326(5956):1123-7. PMC: 2862588. DOI: 10.1126/science.1175868. View

Kwong P, Mascola J . Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37(3):412-25. PMC: 4706166. DOI: 10.1016/j.immuni.2012.08.012. View

Hoxie J, Haggarty B, Bonser S, Rackowski J, Shan H, Kanki P . Biological characterization of a simian immunodeficiency virus-like retrovirus (HTLV-IV): evidence for CD4-associated molecules required for infection. J Virol. 1988; 62(8):2557-68. PMC: 253685. DOI: 10.1128/JVI.62.8.2557-2568.1988. View

Hraber P, Seaman M, Bailer R, Mascola J, Montefiori D, Korber B . Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 2013; 28(2):163-9. PMC: 4042313. DOI: 10.1097/QAD.0000000000000106. View

McClure M, Sattentau Q, Beverley P, Hearn J, Fitzgerald A, Zuckerman A . HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature. 1987; 330(6147):487-9. DOI: 10.1038/330487a0. View

Lynch R, Tran L, Louder M, Schmidt S, Cohen M, DerSimonian R . The development of CD4 binding site antibodies during HIV-1 infection. J Virol. 2012; 86(14):7588-95. PMC: 3416294. DOI: 10.1128/JVI.00734-12. View

McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

10.

Wu X, Yang Z, Li Y, Hogerkorp C, Schief W, Seaman M . Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010; 329(5993):856-61. PMC: 2965066. DOI: 10.1126/science.1187659. View

11.

Li Y, Migueles S, Welcher B, Svehla K, Phogat A, Louder M . Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007; 13(9):1032-4. PMC: 2584972. DOI: 10.1038/nm1624. View

12.

Mouquet H, Scheid J, Zoller M, Krogsgaard M, Ott R, Shukair S . Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010; 467(7315):591-5. PMC: 3699875. DOI: 10.1038/nature09385. View

13.

North B, Lehmann A, Dunbrack Jr R . A new clustering of antibody CDR loop conformations. J Mol Biol. 2010; 406(2):228-56. PMC: 3065967. DOI: 10.1016/j.jmb.2010.10.030. View

14.

Braden B, SOUCHON H, Eisele J, Bentley G, Bhat T, Navaza J . Three-dimensional structures of the free and the antigen-complexed Fab from monoclonal anti-lysozyme antibody D44.1. J Mol Biol. 1994; 243(4):767-81. DOI: 10.1016/0022-2836(94)90046-9. View

15.

Diskin R, Klein F, Horwitz J, Halper-Stromberg A, Sather D, Marcovecchio P . Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med. 2013; 210(6):1235-49. PMC: 3674693. DOI: 10.1084/jem.20130221. View

16.

Zhu J, Wu X, Zhang B, McKee K, ODell S, Soto C . De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc Natl Acad Sci U S A. 2013; 110(43):E4088-97. PMC: 3808619. DOI: 10.1073/pnas.1306262110. View

17.

Kwon Y, Finzi A, Wu X, Dogo-Isonagie C, Lee L, Moore L . Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A. 2012; 109(15):5663-8. PMC: 3326499. DOI: 10.1073/pnas.1112391109. View

18.

Cardoso R, Zwick M, Stanfield R, Kunert R, Binley J, Katinger H . Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 2005; 22(2):163-73. DOI: 10.1016/j.immuni.2004.12.011. View

19.

McGuire A, Hoot S, Dreyer A, Lippy A, Stuart A, Cohen K . Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med. 2013; 210(4):655-63. PMC: 3620356. DOI: 10.1084/jem.20122824. View

20.

West Jr A, Diskin R, Nussenzweig M, Bjorkman P . Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A. 2012; 109(30):E2083-90. PMC: 3409792. DOI: 10.1073/pnas.1208984109. View